Immunotherapy of metastatic breast cancer: Phase I trial of reduced-intensity allogeneic hematopoietic stem cell transplantation with Th2/Tc2 T-cell exchange

Clinical Breast Cancer

Volumn 7, Issue 1, 2006, Pages 87-89

  Hardy, Nancy M ^a   Fowler, Daniel H ^a   Bishop, Michael R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adoptive cellular therapy; Engraftment; Graft engineering; Graft versus host diseases; Graft versus tumor effect; Type 2 cytokines

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BREAST CANCER; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXICITY; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNE RESPONSE; KAPLAN MEIER METHOD; METASTASIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; T CELL DEPLETION; TH2 CELL;

EID: 33744969166     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.019     Document Type: Article

References (12)

1. Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88:1501-1508.
2. Ueno NT, Rondon G, Mirza NQ, et al. Allogeneic peripheral-blood pro genitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998; 16:986-993.
3. Bishop MR. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for metastatic breast cancer. Clin Breast Cancer 2003; 4:39-45.
4. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108:806-814.
5. Champlin RE. T-cell depletion for bone marrow transplantation: effects on graft rejection, graft-versus-host disease, graft-versus-leukemia, and survival. Cancer Treat Res 1990; 50:99-111.
6. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987; 2:175-178.
7. Bishop MR, Fowler DH, Marchigiani D, et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004; 22:3886-3892.
8. Bishop MR, Steinberg SM, Gress RE, et al. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. Br J Haematol 2004; 126:837-843.
9. Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma 2000; 38:221-234.
10. Fowler DH, Gress RE. CD8+ T cells of Tc2 phenotype mediate a GVL effect and prevent marrow rejection. Vox Sang 1998; 74(suppl 2):331-340.
11. Fowler DH, Bishop MR, Gress RE. Immunoablative reduced-intensity stem cell transplantation: potential role of donor Th2 and Tc2 cells. Semin Oncol 2004; 31:56-67.
12. Halverson DC, Schwartz GN, Carter C, et al. In vitro generation of allospecific human CD8+ T cells of Tc1 and Tc2 phenotype. Blood 1997; 90:2089-2096.